ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 9.27
+0.06 (0.65%)
Sep 1, 2026, 4:00 PM EDT
ChemPartner PharmaTech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,616 | 4,761 | 3,185 | 3,809 | 5,184 | 6,882 | |
Market Cap Growth | -27.18% | 49.45% | -16.38% | -26.51% | -24.68% | -6.52% |
Enterprise Value | 4,594 | 4,847 | 3,370 | 4,185 | 5,574 | 8,390 |
Last Close Price | 9.27 | 9.56 | 6.42 | 7.65 | 10.41 | 13.81 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 354.94 | - | - | 13.69 | - |
Forward PE | - | 21.25 | 21.25 | 21.25 | 21.25 | 21.25 |
PS Ratio | 3.97 | 4.20 | 3.28 | 3.35 | 3.91 | 4.07 |
PB Ratio | 3.54 | 3.66 | 2.57 | 2.61 | 2.17 | 3.46 |
P/TBV Ratio | 3.71 | 3.83 | 2.69 | 3.01 | 3.58 | 11.31 |
P/FCF Ratio | 47.58 | 37.18 | 32.19 | - | - | 74.63 |
P/OCF Ratio | 27.95 | 24.99 | 18.94 | 25.23 | 19.75 | 18.20 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.95 | 4.27 | 3.47 | 3.68 | 4.20 | 4.96 |
EV/EBITDA Ratio | 46.78 | 81.79 | - | - | 380.03 | 47.41 |
EV/EBIT Ratio | - | 503.65 | - | - | - | 128.47 |
EV/FCF Ratio | 47.34 | 37.86 | 34.06 | - | - | 90.98 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.27 | 0.36 | 0.42 | 0.44 | 0.41 | 0.88 |
Debt / EBITDA Ratio | 3.62 | 3.79 | 14.86 | 8.58 | 9.94 | 6.73 |
Debt / FCF Ratio | 3.67 | 3.69 | 5.19 | - | - | 18.94 |
Net Debt / Equity Ratio | -0.04 | 0.01 | 0.12 | 0.20 | 0.09 | 0.79 |
Net Debt / EBITDA Ratio | -1.59 | 0.25 | -3.82 | -115.47 | 13.95 | 8.86 |
Net Debt / FCF Ratio | -0.54 | 0.11 | 1.45 | -5.68 | -2.77 | 17.00 |
Asset Turnover | 0.59 | 0.56 | 0.44 | 0.36 | 0.33 | 0.41 |
Inventory Turnover | 53.70 | 77.28 | 39.04 | 24.31 | 17.91 | 18.74 |
Quick Ratio | 1.96 | 1.98 | 1.67 | 1.48 | 1.64 | 0.56 |
Current Ratio | 2.18 | 2.15 | 1.86 | 1.70 | 1.75 | 0.69 |
Return on Equity (ROE) | -3.29% | 1.07% | -16.79% | -47.67% | 17.30% | -18.11% |
Return on Assets (ROA) | -0.59% | 0.30% | -2.74% | -1.31% | -1.49% | 0.98% |
Return on Invested Capital (ROIC) | -1.48% | 0.60% | -6.22% | -3.02% | -1.58% | 1.90% |
Return on Capital Employed (ROCE) | -1.10% | 0.60% | -5.90% | -3.30% | -3.10% | 2.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.93% | 0.28% | -7.11% | -24.07% | 7.30% | -5.85% |
FCF Yield | 2.10% | 2.69% | 3.11% | -1.32% | -1.42% | 1.34% |
Payout Ratio | - | 21.63% | - | - | 9.88% | - |
Buyback Yield / Dilution | 12.31% | 11.17% | -1.01% | -0.02% | -0.31% | 0.64% |
Total Shareholder Return | 12.31% | 11.17% | -1.01% | -0.02% | -0.31% | 0.64% |